The Health and Social Care Committee in the House of Commons today published its latest report on the impact of Brexit on medicines, medical devices and substances of human origin.
We are pleased that it raises issues that we agree need to be considered by the Government to ensure the current approval processes for new treatments are not affected negatively and shared European safety standards for plasma-derived products remain high.
Last year The Haemophilia Society gave evidence to the Health Select Committee and was able to discuss how we ensure people with bleeding disorders retain access to the the newest treatments and the UK continues to be a world-leading place for haemophilia treatment and research following Brexit.
The Full Report is available below:
[embeddoc url=”http://haemophilia.org.uk/wp-content/uploads/2018/03/HSCC-Report-on-Brexit.pdf” download=”all”]